Hearts of Athletes

Hearts of Athletes Study: Prospective Evaluation of Athletes for Cardiac Involvement With COVID-19

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04736004

Enrollment

Registered

2021-02-03

Start date

2022-11-03

Completion date

2025-09-24

Last updated

2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Involvement With COVID-19

Keywords

athletes

Brief summary

The Hearts of Athletes study is being conducted to determine the heart involvement with COVID-19 in athletes. This study aims to enroll any Adult (18 years of age or greater) • Athlete is defined as NCAA Collegiate Athlete, Professional Athlete, Military, or Olympic Athlete will be eligible for the study. With COVID-19 • COVID-19 diagnosed via an RT-PCR (nasal or throat swab test) prior to enrollment Or without COVID-19 • Identified as a local Control participant (similar sport) to a participant with COVID-19, who is willing to undergo a standard cardiovascular evaluation Participants with and without COVID-19 will use their mobile devices to provide health information, like symptoms, by answering survey questions daily for 30 days. Also, participants will allow their de-identified cardiac images to be sent to the Duke Heart Center for blinded analysis. No physical risks are associated with this study. One possible risk, although minimal, is loss of confidentiality.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 30 Years

Inclusion criteria

* Any adult athlete (defined as NCAA Collegiate Athlete, Professional Athlete, or Olympic Athlete) will be eligible for the study. * COVID-19 diagnosed via an RT-PCR, or history of COVID-19 antibodies at least 10 days and less than 6 months prior to consent * No longer requiring quarantine per local health recommendations, prior to cardiovascular evaluation. * Identification as a Control participant (similar sport) to a participant without COVID-19 willing to undergo cardiovascular evaluation

Exclusion criteria

* Anyone with known cardiovascular disease - defined as known myocardial disease, valvular heart disease, or known coronary heart disease * Anyone without the ability to provide informed consent * Anyone with a known contraindication to cardiac magnetic resonance (metallic implant)

Design outcomes

Primary

Measure	Time frame
Rate of Definite Myocarditis as measured by CMR (Cardiac Magnetic Resonance Imaging)	Up to 7 months
Rate of Possible Myocarditis as measured by CMR (Cardiac Magnetic Resonance Imaging)	Up to 7 months

Secondary

Measure	Time frame
Number of abnormal ECGs as measured by medical record abstraction	Up to 7 months
Number of abnormal Troponin as measured by medical record abstraction	Up to 7 months
Number of abnormal echocardiogram as measured by medical record abstraction	Up to 7 months

Countries

United States

Outcome results